Immunotherapy duo aims to shrink stomach tumors before surgery
NCT ID NCT06829797
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding an immunotherapy drug (QL1706) to standard chemotherapy before and after surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 96 participants will be randomly assigned to receive either the combination or chemotherapy alone. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance (pathological complete response) at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tuvonralimab (QL1706) combined with SOX chemotherapy
What this could lead to
If successful, this combination could become a new standard neoadjuvant treatment, potentially improving the chance of complete tumor removal and long-term control for locally advanced gastric cancer.
What could go wrong
This is an early Phase 2 trial with only 96 participants, so results may not be definitive. Adding immunotherapy to chemotherapy can increase side effects, and the benefit over chemotherapy alone is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Provincial Hospital
RECRUITINGJinan, Shandong, 250021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••